MediWound Ltd. Stock Prediction
AI-powered sentiment analysis and prediction trends for MDWD, updated each market day.
MDWD AI Sentiment
AI sees no strong directional signal for MediWound Ltd. stock over the next 10 market days.
Prediction date: Sept. 17, 2026
Exact scores are in the SharePreds app
The precise prediction score for this stock, with buy and sell targets and a stop loss, updated every market day.
About MediWound Ltd.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.
Exchange
Market Cap
$172,352,211
Cap Tier
Employees
121
Listed Since
March 20, 2014
Website
MDWD Sentiment Trend: Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
MDWD Volatility
MediWound Ltd. has shown high price volatility over the last 5 trading days. High volatility means larger price swings: this can present both opportunity and risk for traders.
